Clinical Trial Update: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial [Phase 3]

View source ↗

Summary

Two Phase 3 studies in unfavorable intermediate-risk prostate cancer are evaluating tailored treatment intensity based on a gene risk score. The Guidance Trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: NRG Oncology | Conditions: Prostate Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING